



E98 Comparison of Doxorubicin Versus VP16-Ifosfamide in 
Addition of High Dose Methotrexate as Pre-operative 
Chemotherapy in Osteosarcomas. A Randomized Trial by 
the French Society of Pediatric Oncology
L.B. Brugieres1, C. Kalifa1, J.M. Guinebretiere1, J.C. Gentet2,
T. Philip3, N. Dupouy1, N. Bellon1, C. Rodary1
1Institut Gustave Roussy, Villejuif, France, 2Hospital La Timone, 
Marseille, France, 3Centre LTon BTrard, Lyon,
France
Objectives:  Long  term  cardiac  toxicity  of  Doxorubicin  led  the
French Society Pediatric Oncology to conduct a trial to compare
the efficacy of a combination of HDMTX and Doxorubicin with a
combination of  HDMTX with  VP16-Ifosfamide  (VP-Ifo). The
choice of VP-Ifo was the based on the good response rate obtained
in a previous phase II study of this  combination in pre-treated
osteosarcoma. 
Methods: All patients, less than 20 years, newly diagnosed with non
metastatic limb osteosarcoma could be included in the trial and
randomized to receive 7 courses of HDMTX 12 g/m2 in combina-
tion either with Doxo 70 mg/m2 (2 courses) in arm S or with VP16
75 mg/m2/dx4d – Ifosfamide 3 g/m2/dx4d (2 courses) in arm N.
Postoperative  chemotherapy  was  adapted  to  the  histological
response. The main criteria was the proportion of good histological
responses (<5% viable cells). 
Results: 227 localized limb high-grade OS pts aged 3 to 19 years
have been randomized; 2 pts have been excluded from analysis
because of wrong diagnosis. Surgery was conservative in 212 pts
and radical in 13. Compliance to pre-operative chemotherapy was
good as 85% and 91% of the pts received at least 6 courses of HD
MTX and 2 courses of Doxo or VP-Ifo respectively. Granulopenia
< 0.53 109/l occurred in 58% of the courses in arm S and 77% in
arm N. Good histological response was observed in 43/113 pts
(42%) in arm S and 61/112 (54%) in arm N. The observed differ-
ence between the percentage of good responders between the 2
arms is 12% (p=0.05). For the whole population, the EFS3y is
75% and OS3y 84%. 
Conclusion:  the association of HD MTX and VP-Ifo produces a
significantly higher proportion of good histological response and
will be considered for further studies. 
E99 Gene Therapy of Osteosarcoma: Targeting
Adenoviruses Towards Integrins Increases Transduction 
Efficiency and Tumour Cell Kill in vitro and in vivo
M.A. Witlox, V.W. Van Beusechem, A. De Gast, G.A. Schaap,
H. Bras, P. Van Diest, R. Alemany, D.T. Curiel, H.M. Pinedo, 
W.R. Gerritsen, P.I.J.M. Wuisman
VU University Medical Centre, Amsterdam,
The Netherlands
Conditionally  Replicative  Adenoviruses  (CRAds)  are  attractive
agents for Osteosarcoma (OS) gene-therapy. However, adenovirus
infection  of  OS  is  limited  due  to  low  levels  of  the  coxsackie-
adenovirus receptor  (CAR). Targeting adenoviruses to  another
receptor highly expressed on OS could overcome this limitation.
We found that CAR expression was low or absent on OS. Integrins
alpha-v-beta-3 and alpha-v-beta-5 were found widely expressed on
primaryOS  as  well  as  on  vascular  endothelial  cells  within  the
tumour. We hypothesized that integrins would be valuable targets
to redirect adenoviruses. This hypothesis was tested on four OS
cell lines (MNNG-HOS, MG-63, CAL 72, SaOs-2) and a panel of
primary  OS  cell  cultures.  The  integrins  were  targeted  through
insertion of an integrin-binding RGD motif into the HI loop of the
adenovirus fiber. Targeting enhanced gene transfer efficiency up to
100  fold.  Tumour  specificity  of  a  CRAd  can  be  achieved  via
deletions in viral genes. In this study the CRAd Addelta24 was
used. This CRAd selectively replicates in cells with an abnormal
Rb  pathway.  Targeting  Addelta24  towards  integrins
(Addelta24RGD) showed to be most efficient in killing primary
OS tumour cells in vitro. Twelve days post infection at an MOI of
0,1 Addelta24RGD cells were all dead, while Addelta24 infected
cells  were  unaffected.  Moreover,  Addelta24RGD  injected  into
human primary OS tumours (volume 200mm3) growing on the
flanks of nude mice induced a significant tumour growth delay.
PBS treated control tumours reached 5 times the initial volume
within  10  days.  Addelta24RGD  treated  tumours  exhibited  a
significant growth delay, reaching 1000mm3 after 25 days. 
Conclusion:  This study shows that redirecting adenoviruses towards
integrins can efficiently enhance transduction of OS, resulting in
more  effective  killing  of OS  cells  in vitro and in  vivo in  a fast
growing  OS.  Therefore,  this  therapeutic  approach  may  be  a
potential candidate for the future treatment of OS.
E100 Ewing Tumour (ET) of the Spine – Experience of the 
Cooperative Ewing’s Sarcoma Studies (EI)cess 81–92
S. Ahrens1, M. Kuhlen1, M. Paulussen1, C. Rnbe2, B. Froehlich1,
J. Dunst2, W. Winkelmann2, H. Juergens1
1University Children’s Hospital, Muenster, Germany, 2University 
Hospital, Homburg/Saar, Germany
Objective: To determine prognostic factors for spinal ET and to
document EFS and local control. 
Methods: 116 patients (pts) registered within (EI)CESS from 01/81
to 12/99, representing 7.5% of the study population (1549 pts),
were analyzed. 63 (54%) were male, the median age was 14.5 years
(range: 2 months- 48 years). Initial tumour volume was <100ml in
51 (44%) and &#61619;100 ml in 41 (35%). 27 patients (23%)
presented with metastases at diagnosis. Local therapy was radio-
therapy alone (65%) or surgery ± radiotherapy (31%). EFS was
analyzed according to Kaplan and Meier, comparisons by logrank
test, and risk factors by Cox models. Competing risks analysis was
carried out to assess local and/or systemic failure rates. 
Results: To date (median time under study 104 months), ten-year
EFS was 0.45. Primary metastases (EFS 0.23 versus 0.52 for non-
metastatic  tumours,  p=0.0081),  gender  (EFS  0.34  for  males
versus 0.57 for females, p=0.0083), and initial surgery (EFS 0.17
versus  0.48  for patients  without  initial  surgery, p=0.0792)  had
negative  impact  on  EFS.  Tumour  volume  (EFS  0.36  for
&#61619;100ml versus 0.53 for smaller tumours, p=0.2105) and
local therapy strategy (EFS 0.40 for definitive radiotherapy versus
0.42 for surgery in combination with radiotherapy, p=0.3303) did
not significantly influence the prognosis. Multivariate Cox anal-
yses predicted fair outcome for female patients without primary
metastases  and  without  primary  surgery.  The  cumulative  inci-
dence of local and combined local and systemic failure was 0.28,
compared to an incidence rate of 0.33 for systemic metastases and
other events. 4/116 patients (3.4%) died of complications during
primary  treatment,  1/116  patients  (0.9%)  developed  a  second
malignancy. 
Conclusion:  54/116 (47%) of patients with ET of the spine survived
long term. The local failure rate is increased compared to other
primary tumour sites.S30 EMSOS abstracts
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E101 Neoadjuvant Chemotherapy in Limb Soft
Tissue Sarcoma: The Significance of C-ERBB-4
Expression
O. Merimsky, J. Issakov, Y. Kollender, I. Schwartz, J. Bickels,
G. Flusser, M. Inbar, I. Meller
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Purpose: ErbB-4 is a recently described member of the epidermal
growth factor receptor (EGFR) family. Relatively little is known
about the expression of erbB-4 in human tumours. In the present
study we assessed the possible role of c-erbB-4 expression product
as a tissue marker for STS, and its correlation with the response to
chemotherapy. 
Methods: The histological specimen of 29 patients with STS of a
limb  who had received preoperative doxorubicin-based  chemo-
therapy were studied. The extent of tumour necrosis was evalu-
ated  histologically.  Paraffin  blocks  of  preoperative  incisional
biopsy were available for immune staining (avidin-biotin-peroxi-
dase  technique)  from  29  patients,  and  blocks  of  the  surgical
specimen  after pre-operative  chemotherapy were  available from
27. 
Results:  The  objective  response  rate  to  preoperative  chemo-
therapy was 34%. Wide resection of the tumour was feasible in
12  patients,  marginal  resection  in  14  cases,  amputation  in  2
patients  with  disease  progression,  and  no surgery  in  one  case.
The tumour necrosis was above 90% in 9  patients, 60–90%  in
12,  and less  than  60%  in  7 patients. An increase  in C-erbB-4
expression  was  more  common  in  cases  with  no  response  to
chemotherapy, while no change of or decrease in C-erbB-4 was
more common in responsive tumours (p=0.004). No correlation
could be found between the degree of necrosis or the chemother-
apeutic regimen and the change in expression of c-erbB-4. The
median  DFS  was  longer  for  patients  with  a  decrease  or  no
change  in  expression  of  C-erbB-4  than  for  patients  with
increased expression. 
Discussion: It is believed that post chemotherapy new expression
or  no  down-regulation  of  the  erbB-4  molecule  represents
tumour  aggressiveness  and  increased  capability  of  growth  and
spread.
E102 The Multicentric Epitheloid Hemangioendothelioma 
of Bone: A Case Example and Review of the Literature
J. Hardes, G. Gosheger, C. Gebert, W. Winkelmann
1University Hospital of Münster, Münster, Germany
Epitheloid hemangioendothelioma of bone is a rare primary bone
malignancy. Diagnosis can be difficult for physicians who are not
experienced  with  bone  neoplasms.  We  also  had  difficulties  in
diagnosis and treatment in one of our patients with a multicentric
epitheloid hemangioendothelioma involving the pelvis, left femur
and left  tibia.  We  recommend a  complete  skeletal  survey with
magnetic  resonance  imaging  because  it  can  reveal  previously
undetected lesions  on conventional radiographs. We  performed
an  extraarticular  resection  of  the  hip  joint  including  the  spina
iliaca anterior inferior, resection of the femur, and amputation of
the lower leg. The femur was replaced by a modular endopros-
thesis. The patient is provided with an above-knee prosthesis and
is  able to walk even longer distances  with a cane 2  years after
surgery. In our opinion it is necessary to perform a wide resection
of this tumour in order to treat a patient with a curative intention.
Palliative radiotherapy should only be used for a non-resectable
tumour or in metatatic disease. Chemotherapy is not a treatment
option.
E103 Familial Coping Patterns with Musculosketeal 
Tumours Among Arabs in Israel
P. Elad1, M. Agabaria2, Y. Yagil1,2, E. Barmizada1, I. Meller1
1Nat. Unit of Orhtopedic Oncology, Tel Aviv Sourasky Medical 
Center, Tel Aviv, Israel, 2Bob Shappell School of Social Work,
Tel Aviv, Israel
Rationale: A severe illness, such as cancer, is a challenge not only
for  the  patient  but  the  entire  family.  It  is  the  family’s  task  to
preserve normal life  with  minimal  disruptions  while  simultane-
ously taking care of the ill family member. Coping patterns need to
be  perceived  and  understood  within  socio-cultural  and  ethnic
contexts.
Aims: This study aimed at learning about coping strategies among
Israeli-Arab patients with musculoskeletal cancer and their families.
Population: 45 out of 60 Arab patients treated in the National unit
of orthopedic oncology between 1996 and 2000, (23 males; 22
females & 78% Muslims; 11% Druse persons & 11% Christians)
agreed to be interviewed. 
Methodology:   Interviews  used  open-ended  questions  relating  to
past  acts  and  current  perceptions  of  coping.  The  two  part
questionnaire was based on an adaptation and translation of the F-
copes  questionnaire.  Interviews  were  conducted  in  Arabic
primarily in the patients’ homes between March and June 2000.
Results: 80% believed that they and their family can cope with diffi-
culties arising from illness. 64% claimed that were they to be ill
today they would involve their families with any resulting difficul-
ties. In retrospect 49% did so. Only 22% would and did involve
neighbors in their difficulties. 58% stated they would request help
from community services only 29% did so during the illness. 40%
stated they would consult with a religious leader and when ill 24%
did so. 
Conclusion:  The results indicate a belief in the nuclear family as a
prime resource for coping and a low use of formal and informal
community resources. 
E104 Age Related Variation in the Radiological Appearance 
of Appendicular Osteosarcoma
A. Saifuddin1, J.A.S. Pringle2, J. White3, T.W.R. Briggs4,
S.R. Cannon4
1Royal Nationa Orthopaedic Hospital NHS, London, United Kingdom, 
2Royal National Orthopaedic Hospital NHS, London, United Kingdom, 
3Oldchurch Hospital, London, United Kingdom, 4Royal National 
Orthopaedic Hospital NHS, London, United Kingdom
Aims: To determine whether there is any variation in the radio-
graphic appearances of primary appendicular osteosarcoma with
age at presentation. 
Methods:  62  patients  with  a  pathologically  proven  diagnosis  of
primary osteosarcoma arising in the appendicular skeleton were
retrospectively reviewed. Features including sex, site and various
radiological appearances were noted and compared to the age of
the patient. 
Results: The study group consisted of 33 males and 29 females with
a mean age of 21.5 years (range 6–79 years). No relationship was
identified between bone involved, pattern of bone destruction, size
or location of associated soft-tissue mass with age at presentation.
The mean age of patients whose tumours extended from the meta-
physis into the epiphysis and also to the joint margin was signifi-
cantly  greater  than  those  whose  tumours  were  limited  to  the
metaphyseal region. Degree of matrix mineralization was less in
those patients under 15 years or over 25 years. This finding almost
reached statistical significance. Absence of periosteal reaction and
Codmans triangle was also significantly associated with an older
age of presentation. EMSOS abstracts S31
Conclusion:   Some  features  of  the  radiological  appearance  of
primary appendicular osteosarcoma vary according to the age of
patient at presentation and may result in an erroneous radiological
diagnosis. 
E105 Acute Pancreatitis after Ifosfamide. A Rare but Heavy 
Complication
N. Delepine, S. Alkallaf, B. Markowska, H. Cornille,
I.M. Bigirimana, G. Delepine
Avicenne hospital, Bobigny, France
Ifosfamide is one of the most important drug in treatment of soft
and bone tissue tumours. We use it from 1985 and around 150
courses a year are performed in our unit. We saw only two times a
pancreatitis following continuous infusion of ifosfamide. In 1994
June, a 35-year-old female with fibrosarcoma presented a sympto-
matic pancreatitis following a ifosfamide-vincristine-actinomycine
combination. Ifosfamide was given continuously at the dosage of 3
g/sqm/day, 2 days. The pain was important during 3 weeks and led
to  stop  ifosfamide  therapy  in  this  patient.  Recently,  in  2002
January, we treated a 17-year-old girl with relapsed rhabdomyosa-
rcoma. She received ifosfamide as a single drug at the dose of 3 g/
sqm/day  (theoretically  five  days)  with  corticosteroids  and  anti-
emetics. At the beginning of the third day, she presented dramati-
cally  abdominal pain, vomiting,  was  doubled up. Symptomatic
treatment by antispasmodics was effective associated with stop of
chemotherapy.  Biologic  examination  showed  increased
amylasemia (725 IU the first day, 1077 the second -normal <82-)
and  increased  amylasuria  2208  IU  (Normal  <750),  increased
lipasemia 3478 IU (normal <300). CTScan showed oedematous
pancreas.  Resolution  of  clinical  and  biological  symptoms  was
complete in 3 days. We founded only two reports of acute pancre-
atitis  associated  with  ifosfamide  in  the  literature.  So, we  think
important to monitor routinely serum amylase levels during ifosfa-
mide infusion, to approach the true incidence of this complication
and to be able to determine the necessity of stopping definitively
the use of this drug in patients presenting one time signs of pancre-
atitis. The role of corticoids in the apparition of pancreatitis must
be evoked and leads to avoid, as soon as possible, the association
of corticoids with ifosfamide.
E106 Survival and Prognostic Factors in Osteosarcoma, a 
Retrospective Analysis
J.A.M. Bramer1, M.J.J. Veth1, J. Bras1, J. De Kraker2,
J.W. Vd Eijken1, G.R. Schaap1
1Academic Medical Centre, Ouderkerk A.D. Amstel,
The Netherlands, 2Emma Kinderziekenhuis, Amsterdam,
The Netherlands
Introduction:   Survival  in  osteosarcoma  varies  from  50–80%.  In
literature response to chemotherapy is the most important prog-
nostic factor. Other described factors  are gender, age, tumour-
location and -volume, stage, alkaline phosphataselevel and delay to
treatment. The value of these remains however controversial. Goal
of this study was to assess survival in osteosarcoma patients treated
in  our  institute,  and  to  evaluate  the  value  of  abovementioned
factors.
Methods: Retrospective study of all patients treated in AMC/EKZ
for high-grade extremity osteosarcoma (1985–1996), with mini-
mally 5 years follow up. In case-sheet survey patient- and tumour
characteristics, treatment and results were investigated. Prognostic
factors were related to survival.
Results: 60 patients were treated, 5 lost to follow-up. The 5 years
survival  was  62%.  There  was  no  gender  related  difference  in
survival. Patients aged 10–15 and 15–20 seemed to have worse
survival rates (48% and 57%) then other age groups (73%), this
difference  however  was  not  significant.  Tumour  location  was
mostly  (443 )  around  the  knee,  but  had  no  correlation  with
survival. There were insufficient data to evaluate prognostic value
of tumour volume. Stage (Enneking) was mostly  II-B (survival
65%). All 6 patients with stage III deceased. A clear correlation
occurred between Alkaline Phosphatase and survival (from 82%
with AF<200 to 25% with AF>500). To a lesser extent this was
found for response to chemotherapy: 82% in good, 56% in bad
responders (EOI standard). No significant  correlation occurred
between survival and delay.
Conclusion:  In this patient group survival was comparable with liter-
ature. Gender had no prognostic value. Stage and Alkaline Phos-
phatase level correlated well with survival. To a lesser extent this
was true for response to chemotherapy. More accurate parameters
and a weighted score-system would improve prognostication.
E107 Serum Markers of Bone Turnover in Patients with 
Osteosarcoma of the Extremity Treated with Primary 
Chemotherapy
S. Ferrari, L. Pratelli, R. Turrini, S. Tedioli, L. Loro, C. Forni,
S. Giacomini, G. Bacci
Istituti Ortopedici Rizzoli, Bologna, Italy
Objective: To assess bone turnover in patients with osteosarcoma
treated with primary chemotherapy. 
Methods: 46 patients (median age 17, 7–42) with osteosarcoma of
the extremity entered the study. Blood samples were taken at the
baseline and before surgery. Serum concentration of bone specific
alkaline phosphatase (BALP), and osteocalcin (OC) (markers of
bone  formation),  and  carboxy-terminal  telopeptide  of  type  I
collagen (ICTP) (marker of bone resorption) were measured by
immunometric essay and expressed as ng/mL, m g/L, ng/mL respec-
tively.  All  patients  underwent  surgery  after  good  clinical  and
radiologic response. With a median follow up of 26 months, 31
patients are continuously free of disease. 
Results: At the baseline, serum concentration of BALP, OC, and
ICTP was 48.1±38, 38.2±22, and 1.05±0.5 respectively, and it
changed to 16±9 (p=0.0001) 21±9.7 (p=0.0001), and 1.4±0.5
(p=0.0002)  after  primary  chemotherapy.  Patients  with  a  good
histologic  response  showed  higher  baseline  BALP  serum  level
compared  to  those  with  a  poor  response  (40±42  vs  28±17,
p=0.008) whereas no differences were found in the post primary
chemotherapy  samples  according  to  the  histologic  response.
Patients who relapsed had higher baseline level of BALP (69 vs 39,
p=0.008), OC (47.6 vs 34.1, p=0.06), and ICTP (1.26 vs 0.9,
p=0.09). After primary chemotherapy, relapsing patients showed
persistent higher level of OC (25.9 vs 18.7, p=0.05) and ICTP
(1.62 vs 1.28, p=0.09), but no difference for BALP (17.9 vs 15.1). 
Conclusion:  In patients with osteosarcoma a significant reduction of
bone formation and an increase of bone resorption is induced by
primary  chemotherapy A  higher  bone remodelling  activity  was
observed in patients who relapsed suggesting a relation between
tumour aggressiveness and bone turnover.
E108 Outcome of Flat Bone Sarcomas (other than Ewing’s) 
in Children and Adolescents/a Study of 25 Cases
V. Minard-Colin, C. Kalifa, J.M. Guinebretiere, L. Brugieres, J. 
Dubousset, J.L. Habrand, G. Vassal, O. Hartmann
Institut Gustave Roussy, Villejuif, France
Objective: we analysed the clinical features and outcome of young
patients with non-Ewing’s flat bone sarcoma treated during the era
of contemporary chemotherapy. S32 EMSOS abstracts
Methods: The characteristics and outcome of 25 patients (15 males
and  10  females)  with  primary  or  radiation-related  flat  bone
sarcoma  treated  in  the  Pediatrics  Department  at  the  Institut
Gustave Roussy from 1981 to 1999 were reviewed. 
Results: Twenty patients had osteosarcoma, four chondrosarcoma
and one malignant fibrous histiocytoma. Age at diagnosis ranged
from 2 to 23 years (median, 15 years). Nine tumours were located
in the craniofacial bones, eleven in the pelvis and five in flat bones
at other sites. Four patients had metastatic disease at diagnosis.
Radiation-associated flat bone osteosarcoma was diagnosed in 10/
25 cases. The median time between radiotherapy and the diagnosis
of  secondary  osteosarcoma  was  7  years.  The  projected  overall
survival and event-free survival (EFS) rates at 5 years were 45.1%
(+/- 19%) and 34.3% (+/- 18%) for all 25 patients. The EFS rate
of  patients  with  a  second bone sarcoma was  similar  to  that  of
patients with de novo flat bone sarcoma (p=0.1). The aim of treat-
ment was curative for 24 patients, 23 of whom were treated with
intensive chemotherapy regimens and 19 with surgery. Significant
adverse prognostic factors on survival included incomplete surgical
resection (p=0.001) and used of regimens without pre and postop-
erative  chemotherapy (p=0.007). Nine  of  the  25  patients  were
treated  with  pre  and  postoperative  chemotheray  and  complete
surgical resection. Among them, eight are alived with no disease. 
Conclusion: Radical surgical resection is the overriding prognostic
factor for flat bone sarcomas in young patients. Nevertheless, our
Results  suggest  a  more  favorable  outcome  since  the  advent  of
intensive chemotherapy. 
E109 CD44 Is a Prognostic Marker in Soft Tissue Sarcoma
M. Peiper, T. Sato, W.T. Knoefel, D. Zurakowski, J.R. Izbicki
University Hospital Hamburg-Eppendorf, Hamburg, Germany
Background: The expression of CD44 has been identified as prog-
nostic factor in several malignant diseases. However, only few data
exist  correlating  CD44  expression  in  soft  tissue  sarcoma  with
subsequent tumour progression or recurrence. The purpose of this
study was to investigate the clinical significance of CD44s in adult
soft tissue sarcoma (STS).
Methods: Tumour specimens of 62 patients with STS were evalu-
ated  regarding CD44s  expression  using  immunohistochemistry.
The  significance  of  the  proposed  prognostic  indicators  was
evaluated in relation to survival and local recurrence.
Results and Conclusion: Of 62 analysed specimens, 49 tumours were
CD44s  positive  compared  to  13  CD44s  negative  tumours.
Kaplan-Meier  survival  analysis  indicated  significantly  better
survival  among  patients  whose  tumour  was  CD44s  positive
(P=0.015). Variables predictive of longer survival included resec-
tion quality (R0, P<0.01) and tumour size (T1, P=0.02). CD44s
expression  correlates  with  prognosis  of  soft  tissue  sarcomas.
CD44s may, therefore, play a pathogenetic role in tumour progres-
sion Determining the expression of CD44s in primary STS could
be a valuable tool for selecting patients for further adjuvant treat-
ment. Nevertheless, radical resection at initial  surgery plays the
pivotal role in soft tissue sarcoma treatment.
E110 Treatment of Advanced Pelvic Osteosarcoma with 
Chemotherapy Directly Inside the Tumour. Case Report.
N. Delepine, S. Alkallaf, B. Markowska, H. Cornille,
I.M. Bigirimana, G. Delepine
Avicenne hospital, Bobigny, France
Introduction:  Very large tumours of pelvis may seem inoperable and
are often treated by palliative radiotherapy and chemotherapy. We
present here a case with intratumoural chemotherapy and mid-
term result.
Case report: This girl, 16 years old, came from Africa in 2000 July,
for a huge tumour of pelvis after 2 years of pelvic pain. A needle
biopsy confirmed the diagnosis of high-grade osteosarcoma. Initial
screening showed a huge tumour (15 cm3 123 10) developed from
the  right  acetabulum,  with  compression  of  bladder  and  both
ureters. The dilatation of kidney cavities led to perform a bilateral
ureterostomy.  Conventional  chemotherapy  didn’t  obtain  any
response and the patient was sent in a palliative care unit after 2
months  of  an  ineffective  treatment.  In  October  2000,  she  was
referred for treatment  in our unit. We started by intratumoural
debulking and put inside the tumour cavity a chemotherapy infu-
sion catheter. Following 3 courses of intratumoural chemotherapy
(CDDP  25  mg)  associated  with  systemic  chemotherapy,  new
debulking surgery  was  performed and the  normal urinary tract
could  be  repaired.  Both  intra-tumour  and  intravenous  chemo-
therapy  were  continued and in October  2001,  the last  tumour
residual was removed and a composite acetabular reconstruction
performed.
Result: In January 2002, the patient is in complete remission. She
can walk, go to school and live normally. The hip function rate
according to Enneking’s criteria is excellent.
Conclusion:  Advanced sarcoma can sometimes benefit of an indi-
vidualized treatment including intratumoural chemotherapy. 
E111 Ewing Sarcoma of the Mobile Spine – Report on 14 
Cases
A. Gasbarrini1, S. Bandiera1, F. de Iure1, S. Ferrari2, P. Bacchini2, 
A. Barbieri3, P. Picci2, L. Boriani1, S. Boriani1
1Dept. of Orthopedics and Traumatology, Maggiore Hospital, Bologna, 
Italy, 2Istituti Ortopedici Rizzoli, Bologna, Italy, 3S. Orsola Hospital, 
Bologna, Italy
Study Design: Fourteen cases of Ewing sarcoma of the mobile spine
were retrospectively reviewed. 
Objectives: To evaluate the role of surgical and non-surgical treat-
ment of Ewing sarcoma of the spine. Summary of Background
data: Ewing  sarcoma involved very rarely  the  spine;  frequently
occurred during second decade of age. The course of the disease
depends  on  the  aggressiveness  of  the  tumour,  as  well  as  the
treatment. Although the anatomic-characteristics of the spine, pre-
operative-chemo  and  radiation-therapy  combined  to  a  wide
excision seems to be an effective treatment. 
Methods: All charts, radiographs and images were reviewed. The
composite  information  provided  by  this  review  allowed  for
oncologic and surgical staging of these cases. 1 patient underwent
curettage, 5 underwent en bloc excision. All those patients were
submitted to chemo and or radiation therapy too. Eight patients
underwent  decompressive  laminectomy  combined  to  adjuvant
therapies  or  chemo  and  radiation  therapy  only  (palliative
treatment). 
Results: On the series of palliative treatment, six patients submitted
to palliative treatment were found dead at final follow up evalua-
tion,  while  only 2  were  alive  without  evidence of disease. One
patient submitted to intralesional excision were found alive at final
follow up evaluation. In en bloc excision series 3 patients were
found alive and disease free, 1 patient was alive and 2 cases were
dead at final follow up evaluation. Only one local recurrence was
diagnosed and treated by an intralesional excision and radiation
therapy. 
Conclusion:  If confirmed on larger series, pre and post-operative
adjuvant therapies  combined to  a wide excision of the  tumour
seems  to be the first  treatment option for spinal osteosarcoma.
Diagnosis must be certain, based on pathognomonic radiographic
pattern and histologic study. In case of neurologic involvement andEMSOS abstracts S33
pathologic  fracture,  complete  intralesional  excision  and  post-
operative adjuvant therapy would be the therapy of choice.
E112 Osteosarcoma of the Mobile Spine – Report of 16 Cases
S. Boriani1, A. Gasbarrini1, S. Bandiera1, F. de Iure1, L. Boriani1, 
F. Bertoni2, P. Picci2, G. Bacci2
1Maggiore Hospital, Bologna, Italy, 2Istituti Ortopedici Rizzoli, 
Bologna, Italy
Study Design: Sixteen cases of osteosarcoma of the mobile spine
were retrospectively reviewed.
Objectives:  To  evaluate  the  role  of  surgical  and  non-surgical-
treatment of osteosarcoma of the spine. 
Summary of Background data: Osteosarcoma involved very rarely
the spine; frequently occurred in young-adult patients. The course
of the disease depends on the aggressiveness of the tumour, as well
as  the  treatment.  Although  the  anatomic-characteristics  of  the
spine, pre-operative chemo-therapy combined to a wide excision
and post-operative chemo and radiation therapy seems to be an
effective treatment. 
Methods: All charts, radiographs and images were reviewed. The
composite  information  provided  by  this  review  allowed  for
oncologic  and  surgical  staging  of  these  cases.  Six  patients
underwent curettage, 6 underwent en bloc excision, one patient
underwent  palliative  decompression.  All  those  patients  were
submitted  to  chemo  and  or  radiation  therapy  too.  Three
patients  received  radiation  therapy  combined  to  chemotherapy
alone. 
Results:  Three  patients  submitted  to  intralesional-excision  were
found alive and disease free at final follow-up-evaluation. At mean
time three patients were dead. In en bloc excision series 2 patients
were found alive and disease free, 1 patient was alive, but suffering
by lung-metastases  and 3 patients  were dead at final follow-up
evaluation. All patients submitted to adjuvant therapy only were
found dead. One only patient was submitted to a palliative surgery
and was found alive at final follow up evaluation while is already
submitted to adjuvant therapies. 
Conclusion:  If confirmed on larger series, pre and post-operative
adjuvant therapies combined to a wide excision of the tumour and
post-operative radiation therapy seems to be the first  treatment
option for spinal osteosarcoma. Diagnosis must be certain, based
on pathognomonic radiographic pattern and histologic study. In
case of neurologic involvement and pathologic fracture, complete
intralesional excision and post-operative adjuvant therapy would
be the therapy of choice.
E113 Radiofrequency Ablation for Locally Recurrent 
Sarcoma
J.B. Cobb, M.A. Hall-Craggs, A.E. Walker, J.S. Whelan,
J.D. Witt, A. Cassoni, W.R. Lees
University College London Hospitals, London,
United Kingdom
Local recurrence of sarcoma poses one of the most difficult prob-
lems. A small recurrence may trigger an operation that is more
radical than the first, with less chance of cure, because the it is
almost always much more difficult to obtain good margins second
time around. After learning from the group in Leiden of local ther-
apies for benign disease, and having used percutaneous modalities
in the management of liver and lung metastases, we obtained ethics
committee  approval  to  treat  patients  with  relapsed  sarcoma.
Conventional treatment modalities had been rejected by the multi-
disciplinary meeting on the grounds of likely ineffectiveness and
high morbidity. We report on the first 8 cases entered into this
study.
Methods: 8 cases were treated between 1998 and 2001. The path-
ological  diagnoses  were:  3  Chondrosarcoma,  2  Malignant
Fibrous Histiocytoma, 1  Chordoma, 1 ewings  and 1  Fibroma-
tosis.  The  patients  were  aged  between  30  and  82  years.  All
tumours were recurrent, having relapsed after surgery between 1
and 4 times.  RF was used  on 3  occasions in one patient,  and
twice in two locations in one patient. Interstitial Laser Photoco-
agulation and Photodynamic therapy were also used once. Follow
up by has been performed by serial scanning with MRI, or CT or
both.
Results: local control without surgery : 4/6; local effect enabling
surgical success: 2/2. complications: 1 fistula, 1 skin breakdown, 2
neurological damage. All were within an irradiated field.
Conclusion:  RF provides a highly effective alternative to surgery for
early  recurrent  sarcoma  where  surgery  may  be  difficult  or
dangerous. Collateral damage is still a problem in irradiated tissue. 
E114 Skeletal and Soft Tissue Ewing’s Sarcoma: Is there a 
Difference
I.W. Carmichael, R. Grimer
Royal Orthopaedic Hospital, Birmingham, United Kingdom
Some tumours behave differently depending on their site of origin.
Ewing’s-sarcoma of soft-tissues is a rare tumour, and discussions
on treatment are scanty. We set out to compare the mortality and
treatment response between Ewing’s – We performed a retrospec-
tive review of our database. Between 1975 and March 2001, we
identified 402 patients with a definite diagnosis of Ewing’s-group-
sarcoma. There were 349 with skeletal-tumours and 53 with soft-
tissue. The same multidisciplinary-team reviewed all patients. All
tumours were  treated with the most  up to date chemotherapy-
regime available at that time. Surgery and radiotherapy were deter-
mined on an individual basis. There were no differences between
the groups with regard treatment options or modalities. There was
a  significant  difference  between  the  ages  of  the  2  populations
(mean for skeletal 18 years, mean for soft tissue 27 years, t’ test
p<0.0001), the number of Pnet-subtypes in each group (skeletal
28/349 (8%), soft tissue 11/53 (21%), chi square p=0.003), and
Enneking-stage (2% of skeletal  and 26%  of soft tissue  were 2a
(expected  6%),  chi  square  p<0.0001).  However, there  was  no
significant difference in either the overall-survival (skeletal 58%,
soft tissue 53%, p>0.2), or overall disease free survival (skeletal
44%, soft tissue 45%). Similarly, there was no significant differ-
ence  in the overall-rate of  metastases  (skeletal  54%, soft tissue
51%, p>0.2), rate of metastases at diagnosis (skeletal 20%, soft
tissue 19%), or in mortality relating to Enneking-stage or chemore-
sponse. Although the populations were significantly different, the
disease process as defined by mortality and treatment response was
exactly the same. 
Conclusion:  Skeletal and Soft-tissue-Ewings-sarcoma are the same
disease  manifest  in  different  populations, depending  on site  of
origin. It would also seem  that  treatment-Methods found to be
affective in 1 group will be affective across both groups.
E115 Ewing’s Sarcoma and Primary Neuro-Ectodermal 
Tumour of the Soft Tissue: Epidemiology, Prognosis and 
Results of Combined Treatment
N. Fabbri, S. Ferrari, E. Guerra, P. Picci, M. Mercuri
Istituti Ortopedici Rizzoli, Bologna, Italy
Introduction:  Soft tissue Ewing’s sarcoma (ES) and Primary Neuro-
Ectodermal  Tumour  (PNET)  are  rare  high-grade  malignantS34 EMSOS abstracts
neoplasms  presenting  very  similar  features,  considered  strictly
related by most authors. Literature is scant and Results of large
series  are  lacking.  Purpose  of  this  study  was  to  analyse
epidemiology,  risk  factors,  and  Results  of  different  treatment
modalities. 
Methods:  A  retrospective  study  was  undertaken at  the  authors’
Institution.  Epidemiology,  clinico-pathologic  features,  staging,
tumour volume, laboratory tests and different treatment regimens
were investigated. 
Results: Forty-three cases of soft tissue ES-PNET were identified
(23 males, 20 females; average age 29). Most common site was
the lower extremity (26 cases); 40 cases were admitted for treat-
ment, 3 were sent for consultation. In 8 of the 40 cases admitted
for treatment there was evidence of metastatic disease. Average
tumour  largest  dimension  was  11  cm  (range: 3–28).  Different
treatment regimens combining chemotherapy, radiotherapy and/
or surgery were used over a period of 20 years. Minimum follow-
up  of  2  years was  available in 37  patients. Overall  disease-free
survival (DFS) is 57% (21 of 37) while continuously disease-free
(CDF)  rate  is  49%  (18  of  37).  Seven  of  the  8  patients  with
metastatic  disease  at  presentation  died.  A  subgroup  of  21
patients with localised disease were homogeneously treated with
contemporary chemotherapy and surgery. At a minimum follow-
up of 2 years, DFS rate for localised disease in this group is 76%
(16 of 21). 
Conclusion:  Soft  tissue  ES-PNET  is  rare, most  common in  the
lower  extremity  during  the  third  decade.  Best  survival  rate
was  associated  with  the  combination  of  chemotherapy  and
surgery. 
E116 Malignancy in Giant Cell Tumour of Bone
E.L. Staals, F. Bertoni, P. Bacchini
Istituti Ortopedici Rizzoli, Bologna, Italy
Objective:  Malignancies  in  giant  cell  tumour  of  bone  are  rare
events, in some cases difficult to recognize. The purpose of this
study was to define the clinicopathologic and histologic features of
these lesions. 
Methods:  We  reviewed  all  cases  of  primary  (PMGCT)  and
secondary (SMGCT) malignancies in giant cell tumour of bone
seen at our institution. PMGCT is a high-grade sarcoma juxta-
posed to areas of benign giant cell tumour (GCT). SMGCT is a
high-grade sarcoma arising on the localization of a GCT previously
treated by surgery or radiotherapy. 
Results: There were 5 PMGCT’s and 12 SMGCT’s. Half of the
SMGCT’s  occurred  after  radiotherapy.  Age  in  patients  with
PMGCT  ranged  from  20  to  68  (median  62),  in  those  with
SMGCT  from  30  to  77  (median  40).  In  both  PMGCT  and
SMGCT the most frequently involved sites were the long bones
around the knee. Latent time between diagnosis of GCT and diag-
nosis of SMGCT was on average 9 years (range 3–15) in patients
subjected to radiotherapy and 18 (range 7–28) in those who had
spontaneous  transformation.  The  high-grade  sarcomas  in
PMGCT were osteosarcomas (4) and malignant fibrous histiocy-
toma (1). The SMGCT’s were osteosarcomas (9), fibrosarcomas
(2) and malignant fibrous  histiocytoma (1). Two patients  with
PMGCT had lung metastasis, one died after 8 months, one is alive
at 40 months. The other patients with PMGCT have no evidence
of disease (NED) 2, 15 and 161 months after the diagnosis. All
patients with post-radiation SMGCT died (after 5, 5, 9, 13, 20 and
148 months). Two of the patients with spontaneous SMGCT died
of metastasis at 2 and 3 months; one died of unrelated cause at 122
months; the other three have NED at 32, 113 and 123 months
after the diagnosis. 
Conclusion: PMGCT and SMGCT are rare high-grade sarcomas
with poor prognoses. 
E117 Solitary Fibrous Tumour of Extrapleural Site. 3 Cases 
with Bone Involvement (Sacrum, Pubic Bone, Radius).
A.R. Von Hochstetter1, G.U. Exner2
1Pathologie Institut Enge, Zurich, Switzerland, 2University of Zurich, 
Orthopaedie, Zurich, Switzerland
Introduction:  Solitary fibrous tumour (SFT) of extrapleural site is a
pathologic entity that has been recognized only recently. We wish
to report 3 consecutive cases with bone involvement to draw the
attention to this diagnosis in musculoskeletal tumours.
Methods:  Three  patients  have  been  diagnosed  to  have  SFTES
and were  treated  by  wide  resection.  Patient  characteristics  are:
Ages  of  the  patients  were  28,  47  and  49  years;  duration  of
symptoms  varied from  2  months  to  4  years; localizations  were
the Sacrum, pubic bone and the radius. Needle biopsies in the
three patients were suggestive of SFT and wide resections were
performed because of the uncertain dignity. At present no recur-
rence  or  metastases  were  observed  at  follow-up  for  30  to  36
months.
Conclusion:  SFT appears to be a soft tissue tumour, that may arise
in parosteal soft tissue and is capable of invading bone. The clinical
behaviour as yet is not determined by histomorphology. In esti-
mating behaviour one must rely on preoperative imaging (infiltra-
tion/metastases)  and  the  complete  pathologic  work-up  of  the
specimen.
E118 Cyclooxygenase-2 Inhibitor for Pain Management in 
Osteoid Osteoma
F. Boettner1, R. Roedl1, K. Wortler2, C. Grethen3,
W. Winkelmann1, N. Lindner1
1Dept. of Orthopaedics, University Hospital of Muenster, Muenster, 
Germany, 2Dept. of Radiology, Klinikum Rechts der Isar, Techn. 
Univ. Muenchen, Munich, Germany, 3Dept. of Orthopaedic Surgery, 
Landeskrankenhaus Salzburg, Salzburg, Germany
Thirteen  patients  with  an  osteoid  osteoma  were  enrolled  in  a
prospective trial to test whether rofecoxib, a selective cyclooxyge-
nase-2 inhibitor, is as effective for pain control as acetylsalicylic
acid. Each patient documented the pain level using a visual analog
scale with 0 being no pain and 10 being unbearable pain during 2
days of no pain medication, 4 days of 500 mg acetylsalicylic acid
three times a day, and 10 days of 25 mg rofecoxib once a day. Oral
administration of 500 mg acetylsalicylic acid three times a day led
to a significant decrease in pain at night, pain at rest, and pain
induced by exercise. Twenty-five milligrams rofecoxib given once
a day at midday showed the same remarkable improvement in pain
at night, pain at rest, and pain induced by exercise. Rofecoxib in
comparison with acetylsalicylic acid showed a trend toward lower
pain levels in all categories. Rofecoxib offered a significantly better
reduction in pain at rest during the day than acetylsalicylic acid.
Results of the current study suggest that pain induction in osteoid
osteoma is related to cyclooxygenase-2, an enzyme that is blocked
by acetylsalicylic acid and rofecoxib. Conservative medical treat-
ment with rofecoxib for osteoid osteoma is recommended when-
ever  percutaneous  intervention  is  associated  with  significant
morbidity.
E119 ‘Dedifferentiated’ Adamantinoma of the Tibia: a New 
Entity
H.M. Hazelbag1, J.B. Laforga2, H. Roels3, P.C.W. Hogendoorn1
1Leiden University Medical Center, Leiden, The Netherlands, 2Surgery 
Hospital Marina Alta, Denia (Allicante), Spain, 3University Hospital, 
Gent, BelgiumEMSOS abstracts S35
In  adamantinoma  of  long  bones,  an  osteofibrous  dysplasia
(OFD-) like form with only scattered epithelial  elements  and a
classic  form  with  abundant  epithelial  component  are  distin-
guished. OFD-like adamantinomas mainly occur in children and
adolescents, behaving relatively benign. Classic  adamantinomas
predominate in adults and have a more aggressive clinical course.
Because  some  OFD-like  tumours  have  progressed  to  classic
adamantinomas,  it  is  currently  accepted  that  the  former  is  a
potential precursor of the latter. Sarcomatous differentiation of
the  epithelial  component in  classic  adamantinoma has  hitherto
been  described  in  only  one  case,  included  in  this  report.  We
studied  3  male  patients  of  83, 63, and 42  years old. The first
patient  had  sarcomatous  dedifferentiation  of  the  epithelial
component in a large primary tibial  adamantinoma. He under-
went amputation and was well at latest follow-up at 23 months.
In the second patient, sarcomatous dedifferentiation was shown
in an en-bloc resected recurrence, 8 months after curretage. The
third patient  had had a  radiologically slowly  progressing osteo-
lytic cortical tibial lesion since the age of 2, a pathological frac-
ture at the age of 5 with subsequent anterior bowing, followed by
en-bloc resection at the age of 37. This tumour showed classic
adamantinoma. A local recurrence 3 years later showed a sarco-
matously dedifferentiated epithelial component. The patient died
of  metastatic  disease  shortly  thereafter.  Histologically,  the
tumours  showed  loss  of  the  original  characteristic  epithelial
differentiation with transition to fields of highly polymorphic cells
with  strong  nuclear  pleomorphism,  high  mitotic  count,  and
deposition of osteoid and chondroid matrix, mimicking osteosar-
coma. However, the immunophenotype was  identical to classic
adamantinoma. 
Conclusion:   This  new  variant  of  adamantinoma  shows  that  in
addition to the mesenchymal-epithelial transformation in the early
stage of development, progression to a more aggressive subtype
may be associated with sarcomatous dedifferentiation (or ‘transdif-
ferentiation’),  in  which  the  epithelial  immunophenotype  is
conserved. 
E120 Adenoviral Delivery of a Secreted form of Human 
Liver Carboxylesterase-2 Sensitizes Osteosarcoma to
CPT-11
M.A. Witlox, D. Oosterhoff, V.W. Van Beusechem, A. De gast, 
F.A. Kruyt, H.J. Haisma, G.R. Schaap, H. Bras, D.T. Curiel, 
H.M. Pinedo, W.R. Gerritsen, P.I.J.M. Wuisman
VU University Medical Centre, Amsterdam, The Netherlands
There are still too many patients who cannot benefit from current
treatment modalities. Therefore, new therapeutic approaches are
warranted. Adenoviral vector (Adv) based suicide gene therapy
could be one such new therapeutic approach. CPT-11 (irinotecan)
is an anticancer agent that can be considered as a prodrug, since it
needs to be converted into SN-38 by the enzyme carboxylesterase
(CE) to reach its full potency. SN-38 is 1000-fold more potent
compared to CPT-11. We hypothesized that a secreted form of CE
produced by tumour cells would diffuse through a tumour mass,
leading to extracellular conversion of CPT-11  to SN-38. Once
formed outside the cell, SN-38 should then more effectively kill
untransduced, neighboring cells. We constructed a secreted form
of human liver CE-2 (sCE2) by deleting of a microsomal retention
signal.  This  sCE2  construct  was  subsequently  cloned  into  a
replication deficient adenoviral vector to produce Ad-sCE2. To
study whether OS cells can be sensitized to CPT-11, four human
OS cell lines (MG-63, MNNG-HOS, Cal-72 and SaOs-2) were
infected with Ad-sCE2. The secreted enzyme was expressed by
infected cells and converted CPT-11 to SN-38, thereby lowering
the IC50 concentration for CPT-11 up to 1000 fold. Most impor-
tantly, primary cisplatin-resistant OS cells, derived directly from a
patient, were sensitized 10 to 100 fold for CPT-11 by infection
with Ad-sCE2. The expected bystander effect was confirmed by
the observation that all tumour cells were effectively killed when
only 1–10% of the cells were infected and a non-toxic concentra-
tion of CPT-11 was administered. Currently, experiments  with
human  OS  xenografts  are  being  performed  to  assess  the  anti-
tumour efficacy of Ad-sCE2 in combination with CPT-11 in vivo.
In Conclusion, combined treatment of OS cells with Ad-sCE2 and
CPT-11  had  a  prominent  effect,  even  on  chemotherapeutic
resistant cells.
E121 Role of Surgery in Local Treatment of Ewing’s 
Sarcoma of the Extremities in Patients Undergoing 
Adiuvant and Neoadiuvant Chemotherapy: 20 Years 
Experience at Rizzoli Institute
S.G. Giacomini1, M.M. Mercuri1, S.F. Ferrari1, D.D. Donati1, 
E.B. Barbieri2, M.M. Manfrini1, C.F. Forni1, F.B. Bertoni1,
G.B. Bacci1
1Istituti Ortopedici Rizzoli, Bologna, Italy, 2Radiotherapy S. Orsola 
Hospital, Bologna, Italy
Background:   Although  more  and  more  patients  with  Ewing’s
sarcoma of bone (ESB) are being treated by surgery, the role of
surgery and radiotherapy in the local treatment of this tumour has
yet to be determined. In fact, because the outcome of ESB may
differ  according  to  the  anatomical  site  of  the  tumour,  Results
reported in literature, which generally refer to series with tumours
located in all sites, may be selection biased. Therefore we have
retrospectively  evaluated  patients  with  ESB  exclusively  in  the
extremity and locally treated by surgery or radiotherapy. 
Methods: 268 patients treated at Rizzoli from 1979 to 1996 for non-
metastatic ESB of the extremities  were assessed. Chemotherapy
was administered according to four sequentially activated proto-
cols. 136 patients were treated by surgery, 70 by surgery and radi-
otherapy and 60 patients by radiotherapy. Two patients underwent
only chemotherapy. 
Results:  Follow-up  ranged  5–23  years  (mean=13years).  152
patients  remained continuously free of disease, 108  relapsed, 2
died of chemotherapy toxicity and 6 developed a second malig-
nancy. The 5-year event-free survival (EFS) and overall survival
(OS) were respectively 62%  and 69%. Although patients  of all
groups were matched for possible risk factors, the rates of 5-year
event-free  survival and local control were  significantly  lower  in
patients treated with radiotherapy compared to patients treated by
surgery or surgery and radiotherapy (48% vs 66%, p=.002; 80% vs
94%, p=.0001). Furthermore, in Group 3 there were 6 secondary
malignancies. 
Conclusion:   Our  Results  seem  to  indicate  that  surgery  should
always  be  considered  in  the  local  treatment  of  ESB  of  the
extremities.
E122 Evaluation of in vitro Effectiveness of Possible 
Candidates for Chemotherapeutic Treatment of Drug-
Unresponsive Osteosarcoma Patients
M Serra, G. Reverter-Branchat, M. Incaprera, K. Scotlandi,
S. Perdichizzi, M.C. Manara, S. Benini, V. Cerisano,
R. Strammiello, P. Piero
Istituti Ortopedici Rizzoli, Bologna, Italy
Development of drug resistance is the most  important cause of
failure of chemotherapy in high-grade osteosarcoma (OS). There-
fore, treatments  planned to circumvent drug resistance  mecha-
nisms may be the basis for therapeutic regimens aimed to increase
the drug response rate of OS patients. The aim of this study was
the  evaluation  of  in  vitro  effectiveness  of  two  drugs  that  canS36 EMSOS abstracts
circumvent some of the most important mechanisms responsible
for  resistance  to  doxorubicin (PNU-159548)  and methotrexate
(trimetrexate). The in vitro cytotoxicity of these agents in combi-
nation with the drugs commonly used in OS chemotherapy were
studied by using a panel of human OS cell lines resistant to doxo-
rubicin, methotrexate and cisplatin, as well as a series of human
OS cell lines established from surgical specimens of high-grade OS
patients. The cells were simultaneously or sequentially exposed to
PNU-159548  or trimetrexate  in combination with doxorubicin,
methotrexate, and cisplatin  and the  effect  of each combination
(additivity,  synergism,  or  antagonism)  was  evaluated  with  the
median effect plot analysis. The Results indicated that OS cells are,
in general, sensitive  to  both PNU-159548  and trimetrexate.  In
particular, PNU-159548  resulted to be active also in OS drug-
resistant cells, being effective against cell lines resistant to doxoru-
bicin, methotrexate and, with a slightly lower efficiency, to cispl-
atin. The in vitro analysis of trimetrexate efficacy demonstrated a
significant effectiveness in all drug-sensitive and drug-resistant OS
cell lines analyzed, with the only exception of cell lines that devel-
oped resistance to MTX through increased levels of dihydrofolate
reductase. Taken together, these data indicate that PNU-159548
and trimetrexate may be considered as promising candidates for
planning new chemotherapeutic regimens to be addressed to high-
grade  OS  patients  who  may  be  refractory  to  conventional
treatments.
E123 Genetic Aberrations Detected by Innovative 
Technologies in Methotrexate-Resistant Human 
Osteosarcoma Cell Lines
C.M. Hattinger, M. Serra, G. Reverter Branchat, M. Incaprera,
K. Scotlandi, S. Benini, M.C. Manara, P. Picci
Istituti Ortopedici Rizzoli, Bologna, Italy
Drug resistance is a multifactorial phenomenon mediated by the
accumulation of genetic changes and therefore requires technolo-
gies that allow genetic analyses on a genome-wide scale. In this
study,  comparative  genomic  hybridization  (CGH)  on  chromo-
somes and CGH on microarrays were used to identify only those
genetic changes that were associated with development of resist-
ance to methotrexate (MTX) in human osteosarcoma (OS) cells.
Red-labeled reference DNAs from the parental drug-sensitive U-
2OS and Saos human OS cell lines were co-hybridized with green-
labeled test DNAs of two series of MTX-resistant variants selected
by stepwise increasing in vitro concentrations of MTX. The direct
comparison  of  MTX-resistant  variants  with  their  respective
parental cell lines by CGH on chromosomes revealed that devel-
opment of MTX resistance was associated with gain of the chro-
mosomal regions 5q12-q15 and 11q14-qter in U-2OS variants and
with gain of 8q22-qter in Saos-2 variants, suggesting the possible
involvement of genes located in these regions. For the identifica-
tion  of  amplified  oncogenes  in  the  MTX-resistant  variants
compared to their  parental MTX-sensitive cell lines, CGH was
performed  on  AmpliOnc  microarrays  (Vysis  Inc)  that  contain
oncogenes known to be frequently amplified in human cancers. In
U-2OS  MTX-resistant variants, amplification of  MLL (11q23)
and gain of FGR (1p36.2-p36.1) gene were consistently found,
whereas  Saos-2  MTX-resistant  variants  displayed  gains  of
different genes depending on the level of resistance. Further anal-
yses by molecular techniques detected amplification of the dihy-
drofolate reductase gene (5q11.2-q13.2), encoding for the target
of MTX, in U-2OS but not in Saos-2 MTX-resistant variants. On
the other hand, fluorescence in situ hybridization showed a rele-
vant increase of C-MYC copy numbers only in Saos-2 variants.
These  Results  suggest  that  genome-wide  analyses  of  MTX-
resistant OS cells by innovative technologies can be considered a
useful tool for the identification of candidate genes that might be
involved in MTX unresponsiveness.
E124 Ewing Tumours of the Spine with Penetration into the 
Spinal Canal Results of the (EI)CESS Studies
M. Kuhlen1, S. Ahrens1, M. Paulussen1, A. Brentrup2,
A. Schuck3, W. Winkelmann4, H. Juergens1
1University Children’s Hospital, Muenster, Germany, 2Dept. of 
Neurosurgery, Muenster, Germany, 3Dept. of Radiotherapy, Muenster, 
Germany, 4Dept. of Orthopedics, Muenster, Germany
Objectives: Ewing tumours (ET) of the spine may be associated
with cord compression. The prognostic impact of tumour penetra-
tion into the  spinal  canal was analysed in pts  registered to the
(EI)CESS studies.
Patients: Between 01/81 and 12/99, 116 pts with ET of the spine
were registered in the (EI)CESS studies, representing 7.5% of the
study population (1549 pts). At diagnosis 32/116 pts presented
with tumour penetration into the spinal canal, 23/32 pts with local-
ised disease, 9/32 pts with metastases to the lungs (6 pts), bone
marrow (1 pt), skeletal system (1 pt) and lymph nodes (1 pt). For
local therapy, 26/32 pts underwent primary surgery (laminectomy
and/or tumour resection) at diagnosis. 4/32 pts underwent surgery
after primary chemotherapy and 2/32 pts received definitive radio-
therapy.  28/30  pts  with  surgery  received  postoperative  radio-
therapy.  Surgery  was  intralesional  in  all  pts,  in  3/30  with
intraoperative damage to the dura.
Results:  To date  17/32  pts  relapsed, 9/17  with  local, 1/17  with
combined, and 7/17 with systemic recurrences. After surgery, 2/2
pts  presented  with  local  recurrences,  after  surgery  with  radio-
therapy,  6/14  with  local,  1/14  with  combined,  and  7/14  with
systemic recurrences (2/7 with primary lung metastases, 1/7 with
primary bone marrow involvement). Of two pts with radiotherapy,
one recurred locally. 3/4 pts with surgery after initial chemotherapy
relapsed. 15/32 pts are in remission. EFS after 10 years was 44%.
The principle relapse site was local recurrence (31%) compared to
8,9% in other primary sites.
Conclusion:  Pts  with  ET  of the  spine with  penetration into  the
spinal canal have an unfavourable prognosis due to failure of local
control.  The  risk  of  dissemination  into  the  spinal  canal  seems
minor at least in pts without opening of the dura. Future treatment
strategies must focus on better local control. 
E125 Bugged Out? Infection and Endoprosthetic 
Replacements
L.M. Jeys, R. Grimer, S. Carter, R. Tillman
Royal Orthopaedic Hospital, Holmfirth, United Kingdom
Introduction:  Endoprosthetic replacement (EPR) following Bone
Tumour excision is common. A major complication of EPRs is
infection, which  can have disastrous  consequences. This  paper
investigates the cause of infection, management and sequalae.
Methods: Over 10,000 patients have been treated over 34 years.
Information  collected  includes  demographic  data,  diagnosis,
treatment  (including  adjuvant),  complications,  and  outcomes.
Data  was  analysed  to  identify  any  infection  in  EPRs,  its
management  and  outcome.  Factors  such  as  operating  time,
blood loss,  adjuvant therapy, type  of  prosthesis  (extendable  or
standard)  were  investigated.  Outcomes  of  treatment  options
were evaluated.
Results: Data was analysed on 1265 patients undergoing EPR over
34 years. Giving a total follow up time of over 6500 patient years.
137  (10.8%)  patients  have been diagnosed with  deep infection
(defined by a positive culture [n=128] or a clinically infected pros-
thesis with pus in the EPR cavity [n=9]).49 (34%) required ampu-
tations  for uncontrollable infection. The  commonest  organisms
were Coagulase Negative Staphylococcus, Staphylococcus aureus
and Group D Streptococci. The only satisfactory limb salvaging
operation was 2 stage revision, which had 71% success in curing
infection. Systemic  antibiotics,  antibiotic  cement  or  beads  andEMSOS abstracts S37
surgical debridement had little chance of curing infection. Infec-
tion rates were highest in the Tibial (23.1%) & Pelvic (22.9%)
EPRs, (p<0.0001). Patients who had pre or post-operative radio-
therapy had significantly higher rates of infection (p<0.0001), as
did patients with extendable EPRs (p=0.007). Patients who had
subsequently  undergone patella  resurfacing  and  rebushing  also
had a higher rate of infection (p= 0.019 & p=0.052).
Conclusion:   Infection is  a serious complication of EPRs.  Treat-
ment  is  difficult  and  prolonged.  2  stage  revision  is  the  only
reliable  method  for  limb  salvage  following  deep  infection.
Prevention  must  be  the  key  to  reducing  the  incidence  of  this
serious complication. 
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Introduction:   Soft  tissue  sarcomas  (STS)  have  a  reported  local
recurrence rate of between 5 and 30 percent. Recurrent tumours
are often similar histologically to the initial tumour, however they
are occasionally of higher histologic grade than the original lesion.
Factors that predispose to this change in grade are not known. We
sought to identify the frequency at which locally recurrent STS
demonstrate a change in histologic grade, and to investigate the
possible factors leading to this change. We also investigate whether
a change in grade is associated with a poorer prognosis. 
Methods: We identified 173 patients who developed locally recur-
rent STS, 116 of which had complete pathologic documentation
who will form the basis of this study. 
Results: Ninety-two patients  (79%) had no change in histologic
grade and 24 (21%) demonstrated an increase in histologic grade.
The mean time to local recurrence was 21 months (range 2–171)
in the unchanged group and 24  months  in the changed group
(range  2–69  months)  (p=0.56).  In  the  unchanged  group  16%
underwent radiotherapy and 17% chemotherapy, while 29% in the
unchanged  group  underwent  radiotherapy  and  none  chemo-
therapy. Univariate analysis of time to local recurrence, histologic
diagnosis and use of radiotherapy did not reveal significant differ-
ences between the groups who did and did not undergo change in
grade. When the diagnosis of MFH was looked at separately, there
was a trend toward a higher proportion in the group that under-
went a grade change. Development of a change in grade was not
associated with a poorer survival rate. 
Conclusion:  Increase in histologic  grade occurs in approximately
20% of locally recurrent STS, but this phenomenon is not associ-
ated with a poorer prognosis than if the grade remains the same.
We were unable to demonstrate any factors that could predict for
a change in histologic grade. 